Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers-Reference-Cited by-同舟云学术

Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers

Published:2014-09-17 Issue:8 Volume:21 Page:1904-1915
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Oberthuer André,Juraeva Dilafruz,Hero Barbara,Volland Ruth,Sterz Carolina,Schmidt Rene,Faldum Andreas,Kahlert Yvonne,Engesser Anne,Asgharzadeh Shahab,Seeger Robert,Ohira Miki,Nakagawara Akira,Scaruffi Paola,Tonini Gian Paolo,Janoueix-Lerosey Isabelle,Delattre Olivier,Schleiermacher Gudrun,Vandesompele Jo,Speleman Frank,Noguera Rosa,Piqueras Marta,Bénard Jean,Valent Alexander,Avigad Smadar,Yaniv Isaac,Grundy Richard G.,Ortmann Monika,Shao Chunxuan,Schwab Manfred,Eils Roland,Simon Thorsten,Theissen Jessica,Berthold Frank,Westermann Frank,Brors Benedikt,Fischer Matthias

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 68 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of MYCN non-amplified neuroblastoma subgroups points towards molecular signatures for precision prognosis and therapy stratification;British Journal of Cancer;2024-03-29

2. Scoring system for diagnosis and pretreatment risk assessment of neuroblastoma using urinary biomarker combinations;Cancer Science;2024-02-27

3. Passenger Gene Coamplifications Create Collateral Therapeutic Vulnerabilities in Cancer;Cancer Discovery;2024-01-13

4. Predicting Neuroblastoma Patient Risk Groups, Outcomes, and Treatment Response Using Machine Learning Methods: A Review;Medical Sciences;2024-01-06

5. The Genetic Basis of the Divergent Clinical Courses in Neuroblastoma;Pediatric Oncology;2024